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Abstract
Background: Changes in lipid profile have long been associated with malignancies as lipids play a
key role in maintenance of cell integrity. This study evaluated the alterations in extended lipid
profile in untreated patients of oral submucous fibrosis (OSMF) and studied the correlation
between lipid levels with tobacco consumption.
Materials and methods: In this hospital-based study, 65 clinically diagnosed and
histopathologically proven patients of OSMF and 42 age and sex matched controls were studied. In
these samples serum lipids including: (i) Total cholesterol, (ii) LDL cholesterol (LDLC), (iii) HDL
cholesterol (HDLC) (iv) VLDL cholesterol (VLDLC) (v) triglycerides (vi) Apo-A1 (viii) Apo-B and
(viii) LPa were analyzed.
Results: A significant decrease in plasma total cholesterol, HDLC and Apo-A1 was observed in
patients with OSMF as compared to the controls. Thus an inverse relationship between plasma lipid
levels and patients was found in OSMF.
Conclusion: The lower levels of plasma cholesterol and other lipid constituents in patients might
be due to their increased utilization. The findings strongly warrant an in-depth study of alterations
in plasma lipid profile in patients with oral precancerous conditions.
Background
Oral submucous fibrosis (OSMF) is a chronic disease of
the oral cavity, which is characterized by an epithelial and
subepithelial inflammatory reaction followed by fibroe-
lastic changes in the submucosa [1]. This disease occurs
most commonly in South East Asia but cases have been
reported worldwide in countries like Kenya, China, UK,
Saudi Arabia and other parts of the world [2]. In India, the
authors earlier reported that oral submucous fibrosis con-
stituted the highest number of patients in premalignant
group in a tertiary level hospital based study at Allahabad
[3]. Tilakaratne et al. reported that areca nut is the main
etiological factor for OSMF [4]. Pandya et al., again from
Allahabad, confirmed that dohra/paan masala containing
areca nut is a major risk factor of OSMF, especially in the
younger age group. They also reported an increase in his-
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topathological grading with severity and duration of
addiction habit [5]. Excessive use of areca nut may cause
fibrosis due to increased synthesis of collagen and induce
the production of free radicals and reactive oxygen spe-
cies, which are responsible for high rate of oxidation/per-
oxidation of polyunsaturated fatty acids which affect
essential constituents of cell membrane and might be
involved in tumorigenesis [6,7].
Lipids are major cell membrane components essential for
various biological functions including cell growth and
division of normal and malignant tissues. They are homo-
geneous group of compounds related more by physical
than chemical properties. An alteration in the circulatory
cholesterol levels has been found to be associated in the
etiology of breast cancer and colorectal cancer [8]. How-
ever, only a few reports are available on plasma lipid pro-
file in head and neck lesions [9,10].
A careful search of the literature does not reveal any
research in extended lipid profiles in OSMF, and to the
best of our knowledge this is the first report of its kind.
Materials and methods
A hospital based study was conducted in 65 clinically
diagnosed and histopathologically proven patients of
OSMF attending the outpatient department in the divi-
sion of Otolaryngology of the Swaroop Rani Nehru Hos-
pital, a tertiary level referral hospital affiliated to the Moti
Lal Nehru Medical College, Allahabad, India after the
institutional ethical committee clearance. All the patients
underwent recording of signs, symptoms, detailed history
including habits, histopathology and extended lipid pro-
file estimation. 42 healthy individuals, matched for age
and sex, who had no complaint or any other major illness
in recent past, were included as controls.
Fasting blood samples were collected in plain vials. Serum
was collected after centrifugation and stored at -80°C
until analyzed. Plasma levels of cholesterol, triglycerides,
VLDL, HDL and LDL were calculated by using Autospan
Reagents (Span Diagnostics, India). Simultaneously, Apo-
A1, Apo-B and LPa were estimated by Electrophoresis by
the standard technique. Statistical analysis, including cal-
culation of coefficient of variation and Standard deviation
was performed utilizing SPSS package. (Tokyo, Japan)
Results
Sixty five cases of OSMF were studied. Maximum patients
(30; 46.2%) were in their second decade (21–30 yrs) of
life with a male predominance. According to the addic-
tion habits, 26 (40%) consumed paan masala or dohra (a
locally available combination of slaked lime and areca
nut), 30.8% patients were addicted to betel quid with
tobacco while 16 (24.6%) were smokers. Only 3 (6.6%)
did not have any habit. 12 (18.5%) patients had a burning
sensation in mouth, 16 (24.6%) had ulceration in the oral
cavity, 15 (23%) had excessive salivation while 22
(33.7%) had difficulty in opening the mouth (trismus)
(Figure 1). On clinical grading of trismus, 5 patients were
found to have grade I (>3 cm), 34 had grade II (2–3 cm),
and 26 had grade III (<2 cm) (Table 1). 28 patients con-
sumed paan masala and betel quid with tobacco for 11–
15 years (1–10 times/day), while 17 patients were
addicted for 6–10 years (11–20 times/day) (Table 2).
There was a significant increase in serum total cholesterol,
LDL, VLDL and triglycerides levels (Figure 2, 3, 4). On the
other hand, there was significant decrease in HDL and
Apo-A1 (Figure 5, 6). No change was observed in Apo-B or
Lipoprotein-A (Figure 7, 8) in the patient category com-
pared to the controls (Table 3).
Discussion
Oral submucous fibrosis has always been a challenging
disease with high prevalence in India. In this study, most
of the OSMF cases were in the second and third decades of
life with a male preponderance and addiction to areca
nut. This is in accordance with previous reports from the
authors as well other groups. As this is a disease of multi-
factorial etiology, various workers have proposed differ-
ent theories of causation to establish the exact nature of
the disease [11]. Pan Masala/Dohra were the most signif-
icant risk factor in this study but no correlation was found
with the lipid profile Lipid Research Clinics Coronary Pri-
mary Prevention Trial was a multicentere, double blinded,
placebo-controlled trial of the bile acid sequestrant,
cholestyramine, among type Ha hypercholesterolemic
men, i.e., men with elevated total serum cholesterol due
to low-density lipoprotein cholesterol. The trial tested the
Showing clinical picture (blanching and fibrosis) in oral sub- mucous fibrosis Figure 1
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Table 1: Clinico-pathological attributes in patients of OSMF
Details N = 65 (%)
Age (Years)
≤11–20 07 (10.8)
21–30 30 (46.2)
31–40 17 (26.2)
41–50 04 (6.1)
>51–60 07 (10.8)
Gender
Male 59 (91)
Female 06 (9)
Personal habits
Pan masala or Dohra 20 (30.8)
Betel quid with tobacco 16 (24.6)
Smoker (cigarettes/bidis) 26 (40)
No habit 03 (6.6)
Clinical Symptoms
Burning sensation in mouth 12 (18.5)
Ulceration of oral cavity 16 (24.6)
Difficulty in mouth opening 22 (33.7)
Excessive salivation 15 (23.0)
Clinical Signs
Grade I (>3 cm) 05 (7.7)
Grade II (2–3 cm) 34 (52.3)
GradeIII (< 2 cm) 26 (40)Lipids in Health and Disease 2009, 8:29 http://www.lipidworld.com/content/8/1/29
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hypothesis that long-term reduction of serum cholesterol
leads to a lowered incidence of coronary heart disease. The
results indicate that there is a decrease in plasma choles-
terol levels associated with cancer apparent within 20
months of diagnosis in patients diagnosed with nonlocal-
ized disease. Of the lipoprotein fractions, LDL-C most
clearly reflects the decrease in total cholesterol.
The role of HDL-C and triglycerides in explaining the
overall pattern of total cholesterol change is less clear [12].
Cholesterol is an amphipathic lipid and as such is an
essential structural component of all cell membranes and
of the outer layer of plasma lipoproteins. It is present in
tissues and in plasma lipoprotein either as free cholesterol
or combined with a long-chain fatty acid, as cholesteryl
ester. It is synthesized in many tissues from acetyl-CoA
and is ultimately eliminated from the body in the bile as
cholesterol or bile salts [13]. Lipoprotein transports free
cholesterol in the circulation, where it readily equilibrates
cholesterol in other lipoproteins and in membranes.
Cholesteryl ester is a stored form of cholesterol found in
most tissues. It is transported as cargo in the hydrophobic
core of lipoproteins [14]. So, the fact that cholesterol in a
hydrophobic molecule, which resides in lipoproteins and
cell membranes, raises two questions: (i) how does the
cell sense the level of cholesterol? (ii) how in this choles-
terol specific signaling transmitted to the nucleus for the
regulation of various genes? Recent studies directed to
resolve these questions, led to the discovery of a novel cell
surface cholesterol-sensor designated as receptor-Ck
which was not only shown to be ubiquitously present in
various human organs but also [through its signaling
pathway] regulated various genes involved in cholesterol
homeostasis [HMG CoA synthase; HMG CoA reductase;
Apo-B-specific LDL – receptor]; cell growth [cyclin D; C –
Table 2: Distribution of tobacco consumption in relation to duration and no. of Pan Masala/Betel quids with tobacco/cigarettes/bidis 
smoked/day
Duration in Year Mean No. of Pan Masala/Betel quid with tobacco/cigarettes/bidis smoked/day
1–10 times/day 11–20 times/day Total
1–5 03 04 06 10
6–10 08 08 09 17
11–15 13 18 10 28
16–20 18 06 04 10
Showing Value of Total Cholesterol in patients of OSMF Figure 2
Showing Value of Total Cholesterol in patients of 
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fos; C-myc; p27, etc.]; cell death [Bc1-2] through a 47 kDa
transcription factor [derived from the cleavage of 125 kDa
SREBP] having affinity for genomic sterol regulatory ele-
ment [SRE] sequence as well as through other transcrip-
tion factors [15-19].
Cholesterol is often found distributed non-randomly in
domains in membranes [20]. Recent observations suggest
that cholesterol exerts many of its actions by maintaining
a specialized type of membrane domain, termed "lipid
rafts" in a functional state. Lipid rafts are enriched in cho-
lesterol and sphingolipids, and have been thought to act
as platform through which signal transduction events are
coordinated and pathogens gain entry to infect host cells
[21].
In some malignancies, serum cholesterol undergoes early
and significant changes. Low levels of cholesterol in the
proliferating tissues and in blood compartments could be
due to the rapidly dividing cells in malignancies. Several
prospective and retrospective studies have shown an
inverse association between blood lipid profiles and dif-
ferent cancers. [22]. Some scientists have observed an
inverse trend between lower serum cholesterol and head
and neck cancer as well as esophageal and colon cancers
[9]. Similar findings were reported by Patel et al 2004
[10].
Earlier studies have shown alteration of plasma lipid pro-
files in head and neck and other cancers [10]. Lipids are
Showing Value of S. triglyceride in patients of OSMF Figure 4
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Showing Value of HDL in patients of OSMF Figure 5
Showing Value of HDL in patients of OSMF.
Showing Value of Apo-A1 in patients of OSMF Figure 6
Showing Value of Apo-A1 in patients of OSMF.
Showing Value of Lipoprotein-A in patients of OSMF Bar Figure 7
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important to carry out important biological functions.
Cholesterol is vital for maintenance of integrity of biolog-
ical membranes and cellular uptake. Regulation of choles-
terol is mediated by lipoprotein receptors. Plasma
triglycerides and cholesterol are packed into lipoproteins
for transport. Cholesterol is an essential constituent of
lipoprotein fractions like LDL, HDL and VLDL. Seventy
five percent of the plasma cholesterol is transported in the
form of LDL. Cells sequester cholesterol from LDL frac-
tion of lipoproteins. Kesaniemi et al reported that LDL
receptors are necessary for metabolizing circulating LDL
levels and nearly 80% of the plasma LDL is cleared by LDL
receptors [23]. High activity of LDL receptors attributes for
lowering the serum cholesterol levels. The individuals
having deficient or defective LDL receptors remove
plasma LDL at much lower rate and have considerably ele-
vated levels [24].
HDL and Apo-A1 levles may be a useful indicator reflect-
ing initial changes occurring in pre-cancerous and neo-
plastic conditions. A significant decrease in levels of HDL
and Apo-A1 was also observed in this study. This was in
accordance with previous reports [10,25] which reported
that lower HDL is an additional predictor of oral pre-
malignant condition and it might be a consequence of
disease that is mediated by utilization of cholesterol by
membrane biogenesis. Schatzkin et al also observed an
inverse relationship between serum cholesterol and oral
pre-malignant condition [26].
Future strategies
The evidence suggests that precancerous lesions are able
to remodel/metabolize lipids for their growth and to gen-
erate phospholipids membrane. Thus, the identification
and characterization of more enzymes involved in these
pathways will be more important for the proper under-
standing of these steps. Recent progress in molecular biol-
ogy will assist researchers in the near future to identify the
genes and enzymes of lipid metabolic pathways.
The change in lipid levels may have a diagnostic or prog-
nostic role in the early diagnosis or prognostication of
oral premalignant and malignant lesions. The findings
strongly warrant an in-depth study of alterations in
plasma lipid profile in these patients.
Abbreviations
HDL: High Density Lipoprotein; LDL: Low density lipo-
protein; VLDL: Very Low Density Lipoprotein; SRE: sterol
regulatory element; LPa: Lipoprotein A; OSMF: Oral sub-
mucous fibrosis.
Showing Value of Apo-B in patients of OSMF Figure 8
Showing Value of Apo-B in patients of OSMF.
Table 3: Value of Apo-A1, Apo-B, Cholesterol, HDL, LDL, Lp-A & S Triglyceride in OSMF Patients (Total N = 65)
Average
Value
mg/dl
Min-Max Coefficient of
Variation
Standard
Deviation
Normal Value
Min-Max
Cholesterol 125.68 45.95–241.4 29.09% 37.42 130–250
HDL Cholesterol 32.58 15.36–70.4 30.83% 10.04 35–90
LDL Cholesterol 90.61 22.4–180.92 34.35% 31.13 0–129
S-Triglyceride 130.14 15.7–607 52.94% 68.90 60–165
Apo-A1 1.033 0.6–1.42 16.36% 0.169 1.20–1.76
Apo B 0.87 0.32–1.51 26.05% 0.227 0.63–1.76
Lipoprotein A 26.87 0.89–115.8 79.04% 21.24 < 30.0Publish with BioMed Central    and   every 
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